US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|
| INVOKAMET | 50MG;500MG; 50MG;1GM; 150MG;500MG; 150MG;1GM | tablet · oral | JANSSEN PHARMS | Prescription | 8 Aug 2014 |
| INVOKAMET XR | 50MG;500MG; 50MG;1GM; 150MG;500MG; 150MG;1GM | tablet, extended release · oral | JANSSEN PHARMS | Prescription | 20 Sep 2016 |
EMA European Union — centrally authorised medicines
Vokanamet Janssen-Cilag International NV · Authorised · authorised 23 Apr 2014 · ATC A10BD16
Therapeutic indication (EMA)
Vokanamet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: in patients not adequately controlled on their maximally tolerated doses of metformin alone in patients on their maximally tolerated doses of metformin along with other glucose lowering medicinal products including insulin, when these do not provide adequate glycaemic control. in patients already being treated with the combination of canagliflozin and metformin as separate tablets For study results with respect to combination of therapies, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|
| INVOKAMET | 02455404 | 500 MG; 50 MG | TABLET · ORAL | JANSSEN INC |
| INVOKAMET | 02455420 | 50 MG; 1000 MG | TABLET · ORAL | JANSSEN INC |
| INVOKAMET | 02455455 | 1000 MG; 150 MG | TABLET · ORAL | JANSSEN INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|
| US NADAC | INVOKAMET 150-1,000 MG TABLET | $9.57542 | per EA | 23 Sep 2026 |
| US NADAC | INVOKAMET 150-500 MG TABLET | $9.60887 | per EA | 23 Sep 2026 |
| US NADAC | INVOKAMET 50-1,000 MG TABLET | $9.53833 | per EA | 23 Sep 2026 |
| US NADAC | INVOKAMET 50-500 MG TABLET | $9.56363 | per EA | 23 Sep 2026 |
| US NADAC | INVOKAMET XR 150-1,000 MG TAB | $9.53579 | per EA | 23 Sep 2026 |
| US NADAC | INVOKAMET XR 150-500 MG TABLET | $9.56119 | per EA | 23 Sep 2026 |
| US NADAC | INVOKAMET XR 50-1,000 MG TAB | $9.68763 | per EA | 23 Sep 2026 |
| US NADAC | INVOKAMET XR 50-500 MG TABLET | $9.67753 | per EA | 17 Dec 2025 |
| NHS Drug Tariff | Canagliflozin 50mg / Metformin 1g tablets | £39.20 | 60 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Canagliflozin 50mg / Metformin 850mg tablets | £39.20 | 60 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.